FDA Drug Delays Leave Patients in the Dark

Hundreds of FDA-mandated postmarket studies are facing significant delays, some stretching over a decade, leaving patients and healthcare providers in the dark about the long-term safety and efficacy of various drugs and medical devices. These studies, critical for resolving questions that arise after a product's approval, are frequently behind schedule, with some manufacturers still developing study plans years after they were due. This oversight allows potentially harmful products to remain on the market, impacting patient health and wasting healthcare funds.

Concerns are amplified by recent policy changes aimed at accelerating drug approvals, which could increase the burden on the postmarket surveillance system. While the FDA states that delays can have legitimate reasons, critics argue that these requirements are often ineffective. The case of Tavneos highlights these issues, with the drug facing scrutiny for liver damage and alleged manipulation of clinical trial data, despite its approval based on limited safety data and a delayed postmarket study. The FDA is currently attempting to withdraw Tavneos from the market, a move Amgen is contesting.

Further examples include the CustomFlex Artificial Iris with zero patients enrolled in its safety study, Paxlovid's delayed safety study in pregnant women, and the Scandinavian Total Ankle Replacement system which saw numerous adverse events. The opioid painkiller Oxaydo also illustrates the problem, with its postmarket study for abuse deterrence never being completed before the drug was discontinued. These ongoing issues underscore the critical need for timely completion of postmarket studies to ensure patient safety and provide accurate evidence for clinical decision-making.